New York, United States
Innervace, founded in 2020, is a pioneering company in the fields of Biotechnology and Health Care. Headquartered in the United States, it specializes in creating Anatomically-Inspired Living Pathways as part of its mission to unlock the full potential of regenerative medicine.
The company's innovative approach involves developing implantable tissue pathways that serve as pre-formed anatomical structures, intended to restore lost neural connections resulting from brain degeneration or injury. Innervace's flagship initiative aims to replicate the migrostriatal pathway in patients suffering from Parkinson’s disease, a groundbreaking venture with significant therapeutic implications.
In its latest funding round on 08 September 2022, Innervace secured a $40.00M Series A investment from key players including BioAdvance, IP Group, Penn Medicine Co-Investment Program, Deerfield, and WARF Ventures, underscoring strong investor confidence in its potential breakthroughs.
